Search / Trial NCT06613698

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease

Launched by GLAXOSMITHKLINE · Sep 23, 2024

Trial Information

Current as of December 22, 2024

Not yet recruiting

Keywords

Gsk4532990 Alcohol Related Liver Disease Steatohepatitis

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Capable of giving signed informed consent prior to the performance of any study-specific procedures.
  • Able and willing to comply with all study assessments and adhere to the protocol schedule of activities.
  • In the opinion of the investigator, there is a history of alcohol consumption compatible with either ALD or Met ALD.
  • A female participant is eligible to participate after meeting additional pre-defined criteria.
  • Participants must meet predefined stable use requirements of concomitant medications based on study criteria.
  • Exclusion Criteria:
  • Meeting any definition of organ system failure as defined by the North American Consortium for Study of End-stage Liver Disease (NACSELD)
  • Exceeding pre-defined biochemical parameters for Alanine Aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline Phosphatase (ALP), Platelets, International normalised ratio (INR), Albumin, estimated glomerular filtration rate (eGFR), Urine albumin-creatinine ratio (UACR) or Glycosylated Hemoglobin (HbA1c). Other primary causes of liver disease based on study criteria.
  • Current or ongoing malignancy (except for basal cell carcinoma or uterine carcinoma-in-situ) at screening. Participants under evaluation for possible malignancy at screening are not eligible.
  • Prior liver transplant or current listing for liver transplant during the screening period.
  • Chronic or acute, including partial, known portal vein thrombosis.
  • Prior transjugular intrahepatic portosystemic shunt (TIPSS) insertion.
  • Any acute cardiovascular event including myocardial infarction, unstable angina, symptomatic heart failure, or cerebrovascular accident in the 6 months prior to screening.
  • Poorly controlled hypertension
  • Clinical suspicion of rhabdomyolysis during the screening period
  • Clinical suspicion of a bleeding episode during the screening period related to portal hypertension and/or low blood fibrinogen level.
  • Body Mass Index (BMI) \>35 kg/m2 at screening

About Glaxosmithkline

GlaxoSmithKline (GSK) is a global healthcare company dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer. With a strong focus on research and development, GSK specializes in pharmaceuticals, vaccines, and consumer health products. The company is committed to advancing innovative therapies and preventive measures across various therapeutic areas, including respiratory, oncology, immunology, and infectious diseases. GSK's collaborative approach and rigorous clinical trial processes underscore its dedication to delivering safe and effective healthcare solutions that meet the needs of patients worldwide.

Locations

Dallas, Texas, United States

Barcelona, , Spain

Sevilla, , Spain

Detroit, Michigan, United States

Indianapolis, Indiana, United States

Toronto, Ontario, Canada

London, , United Kingdom

Phoenix, Arizona, United States

Los Angeles, California, United States

Adelaide, South Australia, Australia

Richmond, Virginia, United States

Berlin, , Germany

Madrid, , Spain

Valencia, , Spain

Chandler, Arizona, United States

New York, New York, United States

Brandon, Florida, United States

Perth, Western Australia, Australia

New Westminster, British Columbia, Canada

Stockholm, , Sweden

Izmir, , Turkey

San Antonio, Texas, United States

Odense C, , Denmark

London, Ontario, Canada

Liverpool, , United Kingdom

Lille, , France

Marrero, Louisiana, United States

Kagawa, , Japan

Rouen Cedex, , France

Angers Cedex 9, , France

Calgary, Alberta, Canada

Shizuoka, , Japan

Nara, , Japan

Roma, , Italy

Kiel, , Germany

Gunma, , Japan

Tokyo, , Japan

Miami Lakes, Florida, United States

Milano, , Italy

Osaka, , Japan

Bologna, , Italy

Murdoch, Western Australia, Australia

Middlesbrough, , United Kingdom

Saitama, , Japan

Mcallen, Texas, United States

Seoul, , Korea, Republic Of

Santander, , Spain

Ciudad De Mexico, , Mexico

Istanbul, , Turkey

Montreal, Quebec, Canada

Valladolid, , Spain

Ansan, , Korea, Republic Of

Leipzig, , Germany

Melbourne, , Australia

Suwon Gyeonggi Do, , Korea, Republic Of

Bergamo, , Italy

Leeds West Yorkshire, , United Kingdom

Df, , Mexico

Messina, , Italy

Philadelphia, Pennsylvania, United States

Parkville Melbourne, , Australia

Terrebonne, , Canada

Esbjerg, , Denmark

Bobigny Cedex, , France

Creteil Cedex, , France

Padova, , Italy

Chiba, , Japan

Acapulgo, , Mexico

Leon, , Spain

Uppsala, , Sweden

Glasgow Strathclyde, , United Kingdom

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0